December 2020 Quick Question: Emicizumab

Our December, 2020 Quick Question addresses the uncommon incidence of breakthrough bleeds in hemophilia A patient who are being treated with emicizumab [HEMLIBRA], the immunotherapeutic that bypasses factor VIII. Treatment may become an issue in severe hemophilia in which patients develop inhibitors. See our November 29 post, Emicizumab Laboratory Assay Review [click] for some hints on therapy.